TLSI (TriSalus Life Sciences) Other Operating Expense: $-0.00 Mil (TTM As of Mar. 2026)


TLSI TriSalus Life Sciences Inc TLSI
29 GF Score
Price $3.82
GF Value $4.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is TriSalus Life Sciences Other Operating Expense?

TriSalus Life Sciences TLSI +3.80% 29 Other Operating Expense is $-0.00 Mil as of Mar. 2026. GuruFocus rates TLSI with a GF Score™ of 29/100 and a GF Value™ of $4.31 (Modestly Undervalued). The stock has 4 warning signs investors should review.

TriSalus Life Sciences's Other Operating Expense for the three months ended in Mar. 2026 was $-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00 Mil.

TriSalus Life Sciences's quarterly Other Operating Expense declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) and declined from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).

TriSalus Life Sciences's annual Other Operating Expense declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).

TriSalus Life Sciences Other Operating Expense Historical Data

* Premium members only.

The historical data trend for TriSalus Life Sciences's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TriSalus Life Sciences Other Operating Expense Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
0.00 0.00 0.00 -0.00 0.00

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 -0.00
TLSI
29GF Score
TriSalus Life Sciences Inc TLSI
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TriSalus Life Sciences Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.00 Mil mean?
TriSalus Life Sciences (TLSI) has a Other Operating Expense of $-0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on TriSalus Life Sciences and its competitors.
Is TriSalus Life Sciences' Other Operating Expense too high?
TriSalus Life Sciences' current Other Operating Expense is $-0.00 Mil. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Other Operating Expense compare to TMCI and LAB?
TriSalus Life Sciences' Other Operating Expense of $-0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on TriSalus Life Sciences and its competitors. TriSalus Life Sciences's current Other Operating Expense is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.31, compared to a current price of $3.82 — trading 11.4% below its estimated fair value. The current Other Operating Expense is $-0.00 Mil. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Other Operating Expense is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TriSalus Life Sciences (TLSI) Overvalued in 2026?

Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued. The current stock price of $3.82 is trading 11.4% below its estimated GF Value™ of $4.31. GuruFocus considers TriSalus Life Sciences to be Modestly Undervalued.

Key valuation signals for TLSI:

  • Other Operating Expense: $-0.00 Mil
  • GF Value™: $4.31 vs. price of $3.82 (11.4% below fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TriSalus Life Sciences Business Description

Address 6272 W. 91st Avenue, Westminster, CO, USA, 80031
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score

Get the complete analysis for TLSI

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price
$4.31
GF Value